Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Expert consensus on targeted biologic therapy for inflammatory airway diseases (2026 edition)].

Created on 16 Nov 2026

Authors

Chinese Society of Allergy, Chinese Medical Association, Asthma Group of Chinese Thoracic Society, Chinese Medical Association

Published in

Zhonghua yi xue za zhi. Volume 106. Issue 42. Pages 4583-4604. Nov 17, 2026.

Abstract

To standardize the clinical application of biologic targeted therapy for airway inflammatory diseases in China, Chinese Society of Allergy and Asthma Group of Chinese Thoracic Society, Chinese Medical Association, with multidisciplinary experts, developed the"Expert consensus on targeted biologic therapy for airway inflammatory diseases (2026 edition)"using an evidence-based approach, which formulated 15 recommendations. The consensus systematically elaborated on the classification, characteristics, and core inflammatory mechanisms of airway inflammatory diseases; described the mechanisms of action, clinical efficacy, and safety profiles of biologics for asthma, chronic obstructive pulmonary disease, chronic rhinosinusitis and allergic rhinitis, and highlighted upper and lower airway comorbidities and their shared inflammatory pathways, thereby providing a reference for the precise and safe use of biologics in clinical practice.

PMID:
43035280
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement